Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Reduced by Hartford Investment Management Co.

Hartford Investment Management Co. reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,418 shares of the biopharmaceutical company’s stock after selling 85 shares during the quarter. Hartford Investment Management Co.’s holdings in Regeneron Pharmaceuticals were worth $4,070,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in REGN. Brighton Jones LLC grew its stake in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares during the last quarter. American Assets Inc. bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $427,000. Clearbridge Investments LLC grew its stake in shares of Regeneron Pharmaceuticals by 0.7% in the fourth quarter. Clearbridge Investments LLC now owns 3,978 shares of the biopharmaceutical company’s stock worth $2,834,000 after purchasing an additional 26 shares in the last quarter. Huntington National Bank grew its stake in shares of Regeneron Pharmaceuticals by 51.9% in the fourth quarter. Huntington National Bank now owns 919 shares of the biopharmaceutical company’s stock worth $655,000 after purchasing an additional 314 shares in the last quarter. Finally, Thoroughbred Financial Services LLC grew its stake in shares of Regeneron Pharmaceuticals by 20.8% in the fourth quarter. Thoroughbred Financial Services LLC now owns 592 shares of the biopharmaceutical company’s stock worth $421,000 after purchasing an additional 102 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

REGN has been the subject of several recent analyst reports. The Goldman Sachs Group decreased their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating for the company in a research note on Wednesday, April 30th. Argus cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, June 30th. Wells Fargo & Company cut Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 price target for the company. in a research note on Friday. Bank of America cut their price objective on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a report on Thursday, April 17th. Finally, Royal Bank Of Canada lowered Regeneron Pharmaceuticals from a “moderate buy” rating to a “hold” rating and set a $662.00 price objective for the company. in a report on Friday, May 30th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $837.61.

Regeneron Pharmaceuticals Trading Up 2.5%

Shares of NASDAQ REGN opened at $558.87 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $1,211.20. The company has a market cap of $60.34 billion, a price-to-earnings ratio of 14.23, a P/E/G ratio of 2.05 and a beta of 0.33. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $538.05 and a 200-day simple moving average of $604.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company had revenue of $3.03 billion for the quarter, compared to analysts’ expectations of $3.40 billion. During the same period in the prior year, the company earned $9.55 earnings per share. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.